Skip to main content

Table 2 Cost and effect of ACTH and TCH within five years

From: Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china

Item

Status

ACTH

TCH

Deviation

Effect

Disease Free Survival/%

38%

46%

− 8

 

Death/%

2.6%

1.4%

1.2

 

QALY/Year

3.4

3.65

− 0.25

Intervention costsa($)

 

3112

1352

 

Health system costs($)

 

56,425

45,043

 

Cost($)

 

59,537

46,395

13,142

ICER

   

− 52,568

  1. aOther costs included were those of the prevention and treatment of febrile neutropenia and peripheral neuropathy